23866 Federal Register / Vol. 74, No. 97 / Thursday, May 21, 2009 / Notices 

FDA estimates the burden of this 

collection of information as follows: 

TABLE 1.—ESTIMATED ANNUAL RECORDKEEPING BURDEN1

21 CFR Section No. of 

Recordkeepers 

Annual Frequency 

per Recordkeeping 

Total Annual 

Records 

Hours per 

Record Total Hours 

179.25(e), large processors 3 300 900 1 900 

179.25(e), small processors 4 30 120 1 120 

Total 1,020 

1There are no capital costs or operating and maintenance costs associated with this collection of information. 

FDA bases its estimate of burden for 

the recordkeeping provisions of 

§ 179.25(e) on the agency’s experience 

regulating the safe use of radiation as a 

direct food additive. The number of 

firms who process food using irradiation 

is extremely limited. FDA estimates that 

there are 3 irradiation plants whose 

business is devoted primarily (i.e., 

approximately 100 percent) to 

irradiation of food and other agricultural 

products. Four other firms also irradiate 

small quantities of food. FDA estimates 

that this irradiation accounts for no 

more than 10 percent of the business for 

each of these firms. Therefore, the 

average estimated burden is based on: 

Three facilities devoting 100 percent of 

their business to food irradiation (3 × 

300 hours = 900 hours for recordkeeping 

annually); four facilities devoting 10 

percent of their business to food 

irradiation (4 × 30 hours = 120 hours for 

recordkeeping annually). 

No burden has been estimated for the 

labeling requirements in § 179.21(b)(1) 

and (b)(2) and § 179.26(c) because the 

information to be disclosed is 

information that has been supplied by 

FDA. Under 5 CFR 1320.3(c)(2), the 

public disclosure of information 

originally supplied by the Federal 

Government to the recipient for the 

purpose of disclosure to the public is 

not a collection of information. 

Dated: May 14, 2009. 

Jeffrey Shuren, 

Associate Commissioner for Policy and 

Planning. 

[FR Doc. E9–11931 Filed 5–20–09; 8:45 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Diabetes and 

Digestive and Kidney Diseases 

Diabetes Mellitus Interagency 

Coordinating Committee; Notice of 

Meeting 

The National Institute of Diabetes and 

Digestive and Kidney Diseases (NIDDK), 

on behalf of the National Institutes of 

Health (NIH), the Centers for Disease 

Control and Prevention (CDC), and the 

Diabetes Mellitus Interagency 

Coordinating Committee (DMICC), is 

convening an ad hoc planning and 

evaluation meeting to provide a midcourse assessment of ongoing preclinical research efforts supported by 

the Special Statutory Funding Program 

for Type 1 Diabetes Research and to 

discuss possible future directions for 

these efforts. 

Sessions of the meeting will be open 

to the public as indicated below, with 

attendance limited to space available. 

Certain sessions, during which 

confidential information will be 

discussed, will be closed to the public. 

Members of the public planning to 

attend the meeting must register online 

at: http://www.scgcorp.com/ 

Type1Diabetes09/registration.asp. This 

is not a meeting to solicit public 

comment. Therefore, members of the 

public are permitted to attend the open 

sessions as observers only. Individuals 

who plan to attend and need special 

assistance, such as sign language 

interpretation or other reasonable 

accommodations, should inform the 

Contact Person listed below at least 10 

days in advance of the meeting. 

Name: Meeting on Pre-Clinical 

Research Supported by the Special 

Statutory Funding Program for Type 1 

Diabetes Research. 

Place: National Institutes of Health, 

Neuroscience Building, 6001 Executive 

Blvd., Conference Room C, Bethesda, 

MD 20852. 

Date: June 17, 2009. 

Open: 8 a.m. to 8:45 a.m. 

Agenda: Meeting introduction; 

overview of the Type 1 Diabetes—Rapid 

Access to Intervention Development 

(T1D–RAID) research program. 

Closed: 8:45 a.m. to 9:30 a.m. 

Agenda: Mid-course assessment of 

T1D–RAID. 

Open: 9:30 a.m. to 10 a.m. 

Agenda: Overview of the Type 1 

Diabetes Preclinical Testing Program 

(T1D–PTP)—Prevention or Reversal of 

Type 1 Diabetes in Rodent Models. 

Closed: 10 a.m. to 10:30 a.m. 

Agenda: Mid-course assessment of the 

T1D–PTP—Prevention or Reversal of 

Type 1 Diabetes in Rodent Models. 

Open: 10:45 a.m. to 11:15 a.m. 

Agenda: Overview of the T1D–PTP— 

Prevention or Reversal of Diabetic 

Complications in Rodent Models. 

Closed: 11:15 a.m. to 11:45 a.m. 

Agenda: Mid-course assessment of the 

T1D–PTP—Prevention or Reversal of 

Diabetic Complications in Rodent 

Models. 

Open: 12:30 p.m. to 1 p.m. 

Agenda: Overview of the Animal 

Models of Diabetic Complications 

Consortium (AMDCC) research program. 

Closed: 1 p.m. to 2 p.m. 

Agenda: Mid-course assessment of the 

AMDCC. 

Open: 2 p.m. to 2:30 p.m. 

Agenda: Overview of the Type 1 

Diabetes Resource. 

Closed: 2:30 p.m. to 3:15 p.m. 

Agenda: Mid-course assessment of the 

Type 1 Diabetes Resource. 

Open: 3:30 p.m. to 4 p.m. 

Agenda: Overview of Beta Cell 

Biology Consortium (BCBC). 

Closed: 4 p.m. to 5 p.m. 

Agenda: Mid-course assessment of the 

BCBC. 

Contact Person: Julie Wallace, PhD, 

Health Science Policy Analyst, Office of 

Scientific Program and Policy Analysis, 

National Institute of Diabetes and 

Digestive and Kidney Diseases, 9000 

Rockville Pike, Building 31, Room 

9A05, Bethesda, MD 20892, (301) 496– 

6623, wallaceja@niddk.nih.gov. 


dwashington3 on PROD1PC60 with NOTICES
Federal Register / Vol. 74, No. 97 / Thursday, May 21, 2009 / Notices 23867 

Name: Meeting on Pre-Clinical 

Research Supported by the Special 

Statutory Funding Program for Type 1 

Diabetes Research. 

Place: National Institutes of Health, 

Neuroscience Building, 6001 Executive 

Blvd., Conference Room C, Bethesda, 

MD 20852. 

Date: June 18, 2009. 

Open: 8 a.m. to 8:30 a.m. 

Agenda: Overview of the Cooperative 

Study Group for Autoimmune Disease 

Prevention (Prevention Centers) 

research program. 

Closed: 8:30 a.m. to 9 a.m. 

Agenda: Mid-course assessment of the 

Prevention Centers. 

Open: 9 a.m. to 9:30 a.m. 

Agenda: Overview of the 

Immunobiology of Xenotransplantation 

Cooperative Research Program (IXCRP) 

research program. 

Closed: 9:30 a.m. to 10:15 a.m. 

Agenda: Mid-course assessment of the 

IXCRP. 

Open: 10:30 a.m. to 11 a.m. 

Agenda: Overview of the NHP 

Transplantation Tolerance Cooperative 

Study Group (NHPCSG). 

Closed: 11 a.m. to 12:15 p.m. 

Agenda: Mid-course assessment of the 

NHPCSG; discussion of cross-cutting 

themes for strengthening the ongoing 

preclinical research portfolio. 

Open: 12:30 p.m. to 1:30 p.m. 

Agenda: Discussion of future 

opportunities for preclinical research. 

Contact Person: Julie Wallace, PhD, 

Health Science Policy Analyst, Office of 

Scientific Program and Policy Analysis, 

National Institute of Diabetes and 

Digestive and Kidney Diseases, 9000 

Rockville Pike, Building 31, Room 

9A05, Bethesda, MD 20892, (301) 496– 

6623, wallaceja@niddk.nih.gov. 

Please Note: The NIH has instituted 

security measures to ensure the safety of NIH 

employees and property. Upon your arrival at 

the Neuroscience Building, enter through the 

main lobby where you will be greeted at the 

security guard’s desk. Visitors who are not 

NIH employees will be required to show one 

form of identification (for example, a 

government-issued photo ID, driver’s license, 

or passport) and to have their bags searched 

in order to enter the building. You will then 

be issued a visitor badge. In estimating your 

travel time, please allow for these security 

measures, particularly if you are arriving in 

a group. Self-parking is available for a 

maximum of $8 per day. 

A registration link, information about 

the meeting, and the agenda are 

available online: http:// 

www3.niddk.nih.gov/fund/ 

otherType1Diabetes09/. 

Dated: May 12, 2009. 

Sanford Garfield, 

Executive Secretary, DMICC, Division of 

Diabetes, Endocrinology and Metabolic 

Diseases, NIDDK, National Institutes of 

Health. 

[FR Doc. E9–11698 Filed 5–20–09; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Arthritis and 

Musculoskeletal and Skin Diseases; 

Notice of Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Arthritis and Musculoskeletal and Skin 

Diseases Special Emphasis Panel, Mentored 

Career Development, Institutional Research 

Training & Pathways to Independence 

Reviews. 

Date: June 5, 2009. 

Time: 11 a.m. to 12 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, One 

Democracy Plaza, 6701 Democracy 

Boulevard, Bethesda, MD 20892. (Telephone 

Conference Call) 

Contact Person: Charles H. Washabaugh, 

PhD, Scientific Review Administrator, 

Review Branch, NIAMS/NIH, 6701 

Democracy Blvd., Room 816, Bethesda, MD 

20892, 301–451–4838, 

washabac@mail.nih.gov. 

Name of Committee: National Institute of 

Arthritis and Musculoskeletal and Skin 

Diseases Special Emphasis Panel, Building 

Interdisciplinary Research Team (BIRT) II 

RFA. 

Date: June 12, 2009. 

Time: 8 a.m. to 6 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, One 

Democracy Plaza, 6701 Democracy 

Boulevard, Bethesda, MD 20892. (Virtual 

Meeting) 

Contact Person: Charles H. Washabaugh, 

EP Review Branch NIAMS, One Democracy 

Plaza, Suite 800, MSC 4872, 6701 Democracy 

Plaza, Bethesda, MD 20892–4872, 301–496– 

9568, washabac@mail.nih.gov. 

Name of Committee: National Institute of 

Arthritis and Musculoskeletal and Skin 

Diseases Special Emphasis Panel, 

Competitive Revision Reviews. 

Date: June 24, 2009. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Embassy Suites at the Chevy Chase 

Pavilion, 4300 Military Road, NW., 

Washington, DC 20015. 

Contact Person: Michael L. Bloom, Ph.D., 

MBA, Scientific Review Administrator, EP 

Review Branch, NIH/NIAMS, One 

Democracy Plaza, Room 820, MSC 4872, 

6701 Democracy Blvd., Bethesda, MD 20892– 

4872, 301–594–4953, 

Michael_Bloom@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.846, Arthritis, 

Musculoskeletal and Skin Diseases Research, 

National Institutes of Health, HHS) 

Dated: May 14, 2009. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E9–11831 Filed 5–20–09; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Disease, Disability, and Injury 

Prevention and Control Special 

Emphasis Panel (SEP): A CreutzfeldtJakob Disease (CJD) Lookback Study: 

Assessing the Risk of Blood Borne 

Transmission of Classic Forms of 

Creutzfeldt-Jakob Disease, Funding 

Opportunity Announcement (FOA) 

CK09–002, Initial Review 

In accordance with Section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), the Centers for Disease 

Control and Prevention (CDC) 

announces the aforementioned meeting. 

Time and Date: 12 p.m.–3 p.m., June 5, 

2009 (Closed). 

Place: Teleconference. 

Status: The meeting will be closed to the 

public in accordance with provisions set 

forth in Section 552b(c) (4) and (6), Title 5 

U.S.C., and the Determination of the Director, 

Management Analysis and Services Office, 

CDC, pursuant to Public Law 92–463. 

Matters to be Discussed: The meeting will 

include the initial review, discussion, and 

evaluation of ‘‘ A Creutzfeldt-Jakob Disease 

Lookback Study: Assessing the Risk of Blood 

Borne Transmission of Classic Forms of 

Creutzfeldt-Jakob Disease, FOA CK09–002.’’ 

Contact Person for More Information: 

Wendy Carr, Ph.D., CDC, 1600 Clifton Road, 

NE., Mailstop D60, Atlanta, GA 30333, 

Telephone: (404) 498–2276. 

The Director, Management Analysis and 

Services Office, has been delegated the 

authority to sign Federal Register notices 


dwashington3 on PROD1PC60 with NOTICES